Department of Urology, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, Netherlands.
Department of Urology, Foch Hospital, University of Versailles, Saint-Quentin-en-Yveline, 92150 Suresnes, France.
Nat Rev Urol. 2014 Aug;11(8):476-80. doi: 10.1038/nrurol.2014.130. Epub 2014 Jul 1.
Bladder cancer is divided into two entities: non-muscle-invasive (NMIBC) and muscle invasive bladder cancer. NMIBC represents 75% of primary diagnoses and is characterized by frequent recurrence but a low risk of mortality. Throughout urological history, significant progress in detection, diagnosis, and treatment of NMIBC has been made. However, bladder cancer remains a heterogeneous disease with varying pathology, molecular background, diagnostic options, and subsequent therapies for the individual patient. Although significant progress has been made over the years, the improvement of bladder cancer outcomes remains the goal of future research.
非肌肉浸润性膀胱癌(NMIBC)和肌肉浸润性膀胱癌。NMIBC 占原发性诊断的 75%,其特点是频繁复发但死亡率低。纵观泌尿外科学的历史,在 NMIBC 的检测、诊断和治疗方面取得了重大进展。然而,膀胱癌仍然是一种异质性疾病,不同患者的病理、分子背景、诊断选择和后续治疗都有所不同。尽管近年来取得了重大进展,但提高膀胱癌的治疗效果仍是未来研究的目标。